

## Medical Policy Manual

## Draft New Policy: Do Not Implement

### Efbemalenograstim alfa-vuxw (Ryzneuta®)

Requires Step Therapy See "Step Therapy Requirements for Provider Administered Specialty Medications"  
Document at: [https://www.bcbst.com/docs/providers/Comm\\_BC\\_PAD\\_Step\\_Therapy\\_Guide.pdf](https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf)

#### IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

**The proposal is to add text/statements in red and to delete text/statements with strikethrough:  
POLICY**

#### INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication(s)

Ryzneuta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

##### Compendial Uses

- Stem cell transplantation-related indications
- Prophylaxis for chemotherapy-induced febrile neutropenia in patients with solid tumors
- Hematopoietic acute radiation syndrome
- Hairy cell leukemia, neutropenic fever

#### DOCUMENTATION

##### Primary Prophylaxis of Febrile Neutropenia

- Documentation must be provided of the member's diagnosis and chemotherapeutic regimen.
- If chemotherapeutic regimen has a low or intermediate risk of febrile neutropenia (less than 20%), documentation must be provided outlining the member's risk factors that confirm the member is at high risk for febrile neutropenia.

#### COVERAGE CRITERIA

##### Prevention of Neutropenia in Cancer Patients Receiving Myelosuppressive Chemotherapy

Authorization of 6 months may be granted for prevention of febrile neutropenia when all of the following criteria are met:



## Medical Policy Manual

## Draft New Policy: Do Not Implement

- The requested medication will not be used in combination with other colony stimulating factors within any chemotherapy cycle.
- The member will not receive chemotherapy at the same time as they receive radiation therapy.
- The requested medication will not be administered with weekly chemotherapy regimens.
- One of the following criteria is met:
  - The requested medication will be used for primary prophylaxis in members with a solid tumor or non-myeloid malignancies who have received, are currently receiving, or will be receiving any of the following:
    - Myelosuppressive anti-cancer therapy that is expected to result in 20% or higher incidence of febrile neutropenia (FN) (See Appendix A).
    - Myelosuppressive anti-cancer therapy that is expected to result in 10 – 19% risk of FN (See Appendix B) and who are considered to be at high risk of FN because of bone marrow compromise, co-morbidities, or other patient specific risk factors (See Appendix C).
    - Myelosuppressive anti-cancer therapy that is expected to result in less than 10% risk of FN and who have at least 2 patient-related risk factors (See Appendix C).
  - The requested medication will be used for secondary prophylaxis in members with solid tumors or non-myeloid malignancies who experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of chemotherapy) from a prior cycle of similar chemotherapy, with the same dose and scheduled planned for the current cycle (for which primary prophylaxis was not received).

### Other Indications

Authorization of 6 months may be granted for members with any of the following indications:

- Stem cell transplantation-related indications
- Hematopoietic Acute Radiation Syndrome  
Treatment for radiation-induced myelosuppression following a radiological/nuclear incident
- Hairy cell leukemia  
Members with hairy cell leukemia with neutropenic fever following chemotherapy

### CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria.

### APPENDIX

#### Appendix A: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 20% or Higher

This list is not comprehensive; there are other agents/regimens that have an intermediate/high risk for development of febrile neutropenia.

##### Acute Lymphoblastic Leukemia

Select ALL regimens as directed by treatment protocol (see NCCN guidelines ALL)

##### Bladder Cancer

Dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)

##### Bone Cancer

- VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin)

## Medical Policy Manual

## **Draft New Policy: Do Not Implement**

- VDC-IE (vincristine, doxorubicin or dactinomycin, and cyclophosphamide alternating with ifosfamide and etoposide)
- Cisplatin/doxorubicin
- VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin)
- VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin, etoposide)

### Breast Cancer

- Dose-dense AC (doxorubicin, cyclophosphamide) followed by dose-dense paclitaxel
- TAC (docetaxel, doxorubicin, cyclophosphamide)
- TC (docetaxel, cyclophosphamide)
- TCH (docetaxel, carboplatin, trastuzumab)

### Head and Neck Squamous Cell Carcinoma

TPF (docetaxel, cisplatin, 5-fluorouracil)

### Hodgkin Lymphoma

- Brentuximab vedotin + AVD (doxorubicin, vinblastine, dacarbazine)
- Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)

### Kidney Cancer

Doxorubicin/gemcitabine

### Non-Hodgkin's Lymphoma

- CHP (cyclophosphamide, doxorubicin, prednisone) + brentuximab vedotin
- Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) ± rituximab
- ICE (ifosfamide, carboplatin, etoposide) ± rituximab
- Dose-dense CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab
- MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab
- DHAP (dexamethasone, cisplatin, cytarabine) ± rituximab
- ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine) ± rituximab
- HyperCVAD ± rituximab (cyclophosphamide, vincristine, doxorubicin, dexamethasone ± rituximab)
- Pola-R-CHP (polatuzumab vedotin-piiq, rituximab, cyclophosphamide, doxorubicin, prednisone)

### Melanoma

Dacarbazine-based combination with IL-2, interferon alpha (dacarbazine, cisplatin, vinblastine, IL-2, interferon alfa)

### Multiple Myeloma

- VTD-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide + bortezomib)
- DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide)

### Ovarian Cancer

- Topotecan ± bevacizumab
- Docetaxel

### Soft Tissue Sarcoma

- MAID (mesna, doxorubicin, ifosfamide, dacarbazine)
- Doxorubicin
- Ifosfamide/doxorubicin

## Medical Policy Manual

**Draft New Policy: Do Not Implement**

Small Cell Lung Cancer  
Topotecan

### Testicular Cancer

- VeiP (vinblastine, ifosfamide, cisplatin)
- VIP (etoposide, ifosfamide, cisplatin)
- TIP (paclitaxel, ifosfamide, cisplatin)

### Gestational Trophoblastic Neoplasia

- EMA/CO (etoposide, methotrexate, dactinomycin/cyclophosphamide, vincristine)
- EMA/EP (etoposide, methotrexate, dactinomycin/etoposide, cisplatin)
- EP/EMA (etoposide, cisplatin/etoposide, methotrexate, dactinomycin)
- TP/TE (paclitaxel, cisplatin/paclitaxel, etoposide)
- BEP (bleomycin, etoposide, cisplatin)
- VIP (etoposide, ifosfamide, cisplatin)
- ICE (ifosfamide, carboplatin, etoposide)

### Wilms Tumor

- Regimen M (vincristine, dactinomycin, doxorubicin, cyclophosphamide, etoposide)
- Regimen I (vincristine, doxorubicin, cyclophosphamide, etoposide)

Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

## **Appendix B: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 10% to 19%**

This list is not comprehensive; there are other agents/regimens that have an intermediate/high risk for development of febrile neutropenia.

Occult Primary – Adenocarcinoma  
Gemcitabine/docetaxel

### Breast Cancer

- Docetaxel ± trastuzumab
- AC (doxorubicin, cyclophosphamide) + sequential docetaxel (taxane portion only)
- AC + sequential docetaxel + trastuzumab
- Paclitaxel every 21 days ± trastuzumab
- TC (docetaxel, cyclophosphamide)

### Cervical Cancer

- Irinotecan
- Cisplatin/topotecan
- Paclitaxel/cisplatin ± bevacizumab
- Topotecan

Colorectal Cancer  
FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, irinotecan)

Esophageal and Gastric Cancers  
Irinotecan/cisplatin

## Medical Policy Manual

## **Draft New Policy: Do Not Implement**

### Non-Hodgkin's Lymphomas

- GDP (gemcitabine, dexamethasone, cisplatin/carboplatin)
- GDP (gemcitabine, dexamethasone, cisplatin/carboplatin) + rituximab
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) including regimens with pegylated liposomal doxorubicin
- CHOP + rituximab (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) including regimens with pegylated liposomal doxorubicin
- Bendamustine

### Non-Small Cell Lung Cancer

- Cisplatin/paclitaxel
- Cisplatin/vinorelbine
- Cisplatin/docetaxel
- Cisplatin/etoposide
- Carboplatin/paclitaxel
- Docetaxel

### Ovarian Cancer

Carboplatin/docetaxel

### Pancreatic Cancer

FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, irinotecan)

### Prostate Cancer

Cabazitaxel

### Small Cell Lung Cancer

Etoposide/carboplatin

### Testicular Cancer

- BEP (bleomycin, etoposide, cisplatin)
- Etoposide/cisplatin

### Uterine Sarcoma

Docetaxel

Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

## **Appendix C: Patient Risk Factors**

This list is not all-inclusive.

- Active infections, open wounds, or recent surgery
- Age greater than or equal to 65 years
- Bone marrow involvement by tumor producing cytopenias
- Previous chemotherapy or radiation therapy
- Poor nutritional status
- Poor performance status
- Previous episodes of FN
- Other serious co-morbidities, including renal dysfunction, liver dysfunction, HIV infection, cardiovascular disease



## Medical Policy Manual

## Draft New Policy: Do Not Implement

- Persistent neutropenia

### APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### REFERENCES

1. Ryzneuta [package insert]. Singapore: Evive Biotechnology PTE. LTD.; November 2023.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed June 5, 2024
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 3.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/growthfactors.pdf](https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf). Accessed June 6, 2024.
4. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-3212.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Cell Transplantation. Version 1.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/hct.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf). Accessed June 6, 2024.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hairy Cell Leukemia. Version 2.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/hairy\\_cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf). Accessed June 6, 2024.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gestational Trophoblastic Neoplasia. Version 1.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/gtn.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf). Accessed June 6, 2024.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Wilms Tumor (Nephroblastoma). Version 1.2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/wilms\\_tumor.pdf](https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf). Accessed June 6, 2024.

### EFFECTIVE DATE

ID\_CHS